Rainbow Coral (RBCC) S-1 7 Mar 16 IPO registration Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Dec. 31, 2015
Document and Entity Information [Abstract]
Document Type	S1
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Entity Registrant Name	Rainbow Coral Corp.
Entity Central Index Key	1,499,790
Entity Filer Category	Smaller Reporting Company

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2015	Mar. 31, 2015	Mar. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 1,372	$ 5,180	$ 65,373
Prepaid expenses		1,095	841
Inventory	$ 2,736	1,139	5,249
Total current assets	4,108	7,414	71,463
Fixed assets net of accumulated depreciation of $4,473, $2,795 and $7,615 respectively	2,236	$ 3,914	6,282
Security deposits	350
TOTAL ASSETS	6,694	$ 11,328	77,745
CURRENT LIABILITIES
Accounts payable and accrued expenses	229,882	$ 274,684	191,780
Advances payable			149,453
Bank overdraft	284
Related party advances payable	201,005	$ 165,214	131,505
Current portion of convertible notes payable, net of discount of $116,664, $0 and $0, respectively.	59,865
Short-term notes payable	844	$ 13,734	2,843
Current portion of long-term notes payable	13,079
Current portion of accrued interest payable	17,574
Total current liabilities	522,533	$ 453,632	475,581
Convertible notes payable, net of discount of $449,371, $237,643 and $215,716, respectively	14,173	164,238	13,111
Notes payable	28,201	37,352	47,157
Accrued interest payable	12,452	14,127	11,201
TOTAL LIABILITIES	$ 577,359	$ 669,349	$ 547,050
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Common Stock, $0.001 par value; 480,000,000 shares authorized; 10,440,782 shares, 342,106 shares and 228,521 shares issued and outstanding at December 31, 2015, March 31, 2015 and March 31, 2014, respectively	$ 10,441	$ 342	$ 229
Preferred Stock, $0.001 stated value; 20,000,000 shares authorized; 1,000,000, 0 and 0 shares issued and outstanding at December 31, 2015, March 31, 2015 and March 31, 2014, respectively	1,000
Additional paid-in capital	4,017,194	$ 3,264,425	$ 2,463,021
Accumulated deficit	(4,599,300)	(3,922,788)	(2,932,555)
Total stockholders' deficit	(570,665)	(658,021)	(469,305)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 6,694	$ 11,328	$ 77,745

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2015	Mar. 31, 2015	Mar. 31, 2014
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 4,473	$ 2,795	$ 7,615
Current portion of convertible notes payable discount	116,664
Noncurrent convertible notes payable discount	$ 449,371	$ 237,643	$ 215,716
Preferred Stock, par value per share	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, shares authorized	20,000,000	20,000,000	20,000,000
Preferred Stock, shares issued	1,000,000	0	0
Preferred Stock, shares outstanding	1,000,000	0	0
Common Stock, par value per share	$ 0.001	$ 0.001	$ 0.001
Common Stock, shares authorized	480,000,000	480,000,000	480,000,000
Common Stock, shares issued	10,440,782	342,106	228,521
Common Stock, shares outstanding	10,440,782	342,106	228,521

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
REVENUE	$ 28,040	$ 28,182	$ 84,387	$ 99,503	$ 128,133	$ 113,009
COST OF GOODS SOLD	9,183	10,592	34,097	48,327	69,745	113,228
GROSS PROFIT	$ 18,857	17,590	50,290	51,176	58,388	(219)
OPERATING EXPENSES
Expenses related to joint ventures and other business development agreements		10,000	15,000	70,000	80,000	85,000
General and administrative expenses	$ 157,049	$ 137,213	$ 583,814	$ 408,144	$ 564,387	557,031
Impairment of goodwill						27,868
LOSS FROM OPERATIONS	$ (138,192)	$ (129,623)	$ (548,524)	$ (426,968)	$ (585,999)	(670,118)
OTHER EXPENSE
Interest expense	(41,566)	(121,858)	(127,988)	(360,550)	(404,234)	(427,023)
NET LOSS	$ (179,758)	$ (251,481)	$ (676,512)	$ (787,518)	$ (990,233)	$ (1,097,141)
NET LOSS PER COMMON SHARE - Basic and diluted	$ (0.02)	$ (0.77)	$ (0.09)	$ (2.71)	$ (3.27)	$ (6.59)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - Basic and diluted	10,260,906	325,418	7,183,130	290,241	302,693	166,360

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Common Stock [Member]	Series E Preferred Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
BALANCE at Mar. 31, 2013	$ 125		$ 1,600,331	$ (1,835,414)	$ (234,958)
BALANCE, SHARES at Mar. 31, 2013	125,200
Shares issued for conversion of notes payable	$ 104		446,005		446,109
Shares issued for conversion of notes payable, shares	103,321
Discount on issuance of convertible notes payable			$ 416,685		416,685
Net loss				$ (1,097,141)	(1,097,141)
BALANCE at Mar. 31, 2014	$ 229		$ 2,463,021	$ (2,932,555)	$ (469,305)
BALANCE, SHARES at Mar. 31, 2014	228,521				228,521
Shares issued for conversion of notes payable	$ 113		401,469		$ 401,582
Shares issued for conversion of notes payable, shares	113,585
Discount on issuance of convertible notes payable			$ 399,935		399,935
Net loss				$ (990,233)	(990,233)
BALANCE at Mar. 31, 2015	$ 342		$ 3,264,425	(3,922,788)	$ (658,021)
BALANCE, SHARES at Mar. 31, 2015	342,106				342,106
Shares issued for conversion of notes payable	$ 10,094		189,865		$ 199,959
Shares issued for conversion of notes payable, shares	10,093,994
Discount on issuance of convertible notes payable			423,909		423,909
Preferred stock issued for control		$ 1,000	$ 139,000		$ 140,000
Preferred stock issued for control (in shares)		1,000,000
Share rounding on reverse split	5		(5)
Share rounding on reverse split (in shares)	4,682
Net loss				(676,512)	$ (676,512)
BALANCE at Dec. 31, 2015	$ 10,441	$ 1,000	$ 4,017,194	$ (4,599,300)	$ (570,665)
BALANCE, SHARES at Dec. 31, 2015	10,440,782	1,000,000			10,440,782

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$ (676,512)	$ (787,518)	$ (990,233)	$ (1,097,141)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on convertible notes payable	95,517	343,385	378,008	398,067
Depreciation	1,678	$ 3,780	$ 2,368	$ 5,854
Preferred stock issued for control	$ 140,000
Impairment of goodwill				$ 27,868
Impairment of inventory				14,500
Changes in operating assets and liabilities:
Inventory	$ (1,597)	$ (3,073)	$ 4,110	9,271
Prepaid expenses	1,095	$ 491	$ (254)	$ (491)
Security deposits	(350)
Accounts payable and accrued liabilities	(44,802)	$ 128,616	$ 207,963	$ 74,429
Accrued interest payable	30,141	17,165	26,228	35,825
NET CASH USED IN OPERATING ACTIVITIES	$ (454,830)	$ (297,154)	$ (371,810)	(531,818)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets				(6,708)
NET CASH USED IN INVESTING ACTIVITIES				(6,708)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from advances	$ 423,909	$ 237,187	$ 276,822	432,683
Proceeds from related party advances	$ 35,791	21,926	$ 33,709	38,442
Repayments of related party advances				(1,818)
Proceeds from notes payable		$ 3,930	$ 5,000	$ 50,000
Repayments of notes payable	$ (8,962)		(3,914)
Bank overdraft	284
NET CASH PROVIDED BY FINANCING ACTIVITIES	451,022	$ 263,043	311,617	$ 519,307
NET DECREASE IN CASH	(3,808)	(34,111)	(60,193)	(19,219)
CASH, at the beginning of the period	5,180	65,373	65,373	84,592
CASH, at the end of the period	1,372	$ 31,262	$ 5,180	$ 65,373
Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for: Interest	$ 2,330
Cash paid during the period for: Taxes
Noncash investing and financing activities:
Refinance of advances into convertible notes payable		$ 125,059	$ 426,275	$ 416,685
Refinance of accounts payable into convertible notes payable	$ 423,909	386,640	125,059
Beneficial conversion discount on convertible notes	423,909	360,299	399,935	$ 416,685
Conversion of convertible notes to common stock	$ 199,959	$ 369,322	$ 401,582	$ 446,109

Background Information

Background Information	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background Information	Note 1. General Organization and Business Rainbow Coral Corp. (the “Company”), a Nevada corporation, was incorporated on August 13, 2010. The Company’s year-end is March 31. We were formed to build a coral farm facility to develop and propagate (or grow) live coral, independent of the oceans, as a future farm reserve against the decline of natural wild reefs. We intend to grow, harvest, and distribute as many varieties of hard and soft sizes as possible of captive-bred corals that are attractive, to as many consumers as possible who can maintain them in a healthy ecosystem aquarium. We believe that coral and other marine aquarium livestock should be supplied by farms or captive breeders, rather than removed from the natural reefs. The additional uses for coral as a source of potential leading edge medical discoveries are an attractive opportunity for the Company’s coral farming activity. We believe that the world of bioresearch is a natural continuation of our core coral propagation business. Accordingly, on October 23, 2011, we formed a subsidiary, Rainbow Biosciences, LLC to look into the opportunities within the bioscience market. Rainbow Biosciences, LLC will continue to research opportunities into the bioscience markets. On May 5, 2015, we reincorporated from Florida to Nevada. On May 29, 2015, each shareholder received one share in the Nevada company for each 100 shares they held in the Florida company. Fractional shares were rounded up, and each shareholder received at least five shares. The executive officers and directors of the Nevada company are unchanged from the executive officers and directors of the Florida company. All share and per share amounts have been retroactively restated to reflect the reverse split. Joint Ventures On March 13, 2012, the Company entered into a stock purchase agreement (“N3D Stock Purchase Agreement”) with Nano3D Biosciences, Inc. (“N3D”), a Texas corporation that has developed a unique concept in three dimensional cell research tools. Under the terms of the N3D Stock Purchase Agreement, the Company agreed to acquire 604 shares of common stock of N3D, representing approximately 5% of the outstanding shares on the date of the agreement, for a price of $413.62 per share. The total purchase price of $249,826 was to be paid by making weekly payments of $5,000 until fully paid. Under the terms of the N3D Stock Purchase Agreement, we could discontinue payment of the purchase price at any time by providing written notice to N3D. The Company invested $60,000 in N3D resulting in the acquisition of 145 shares of N3D’s common stock. The Company suspended payments to N3D in May 2012 because of their delay in reaching certain milestones in the commercialization process. The Company wrote off the investment in full due to the uncertainty about whether the carrying amount is recoverable. During the nine months ended December 31, 2015, the Company paid and expensed $10,000 with N3D. On February 1, 2013, the Company entered into a joint venture agreement with TheraKine Ltd. (“TheraKine”) in order to explore potential business opportunities to exploit TheraKine’s drug delivery technologies. TheraKine is the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before. During the nine months ended December 31, 2015, the Company made no payments toward this joint venture.	Note 1. Background Information RAINBOW CORAL CORP. (the “Company”) was formed to build a coral farm facility to develop and propagate (or grow) live coral, independent of the oceans, as a future farm reserve against the decline of natural wild reefs. We intend to grow, harvest, and distribute as many varieties of hard and soft sizes as possible of captive-bred corals that are attractive, to as many consumers as possible who can maintain them in a healthy ecosystem aquarium. We believe that coral and other marine aquarium livestock should be supplied by farms or captive breeders, rather than removed from the natural reefs. The additional uses for coral as a source of potential leading edge medical discoveries are an attractive opportunity for the Company's coral farming activity. We believe that the world of bioresearch is a natural continuation of our core coral propagation business. Accordingly, on October 23, 2011, the Company formed a subsidiary, Rainbow Biosciences, LLC to look into the opportunities within the bioscience market. Rainbow Biosciences, LLC will continue to research opportunities into the bioscience markets. The Company was incorporated in Florida on August 13, 2010. The Company's fiscal year end is March 31. On May 29, 2015, we reincorporated from Florida to Nevada. Each shareholder received one share in the Nevada company for each 100 480 20 0.001 All share and per share amounts have been retroactively restated in the accompanying financial statements and notes to financial statements to reflect this reverse stock split. Joint Ventures On March 13, 2012, the Company entered into a stock purchase agreement (“N3D Stock Purchase Agreement”) with Nano3D Biosciences, Inc. (“N3D”), a Texas corporation that has developed a unique concept in three dimensional cell research tools. Under the terms of the N3D Stock Purchase Agreement, the Company agreed to acquire 604 5 413.62 249,826 5,000 60,000 145 The Company discontinued payments to N3D in May 2012 because of their delay in reaching certain milestones in the commercialization process. The Company wrote off the investment in full due to the uncertainty about whether the carrying amount is recoverable. During the year ended March 31, 2015, the Company paid and expensed $ 60,000 On February 1, 2013, the Company entered into a joint venture agreement with TheraKine Ltd. (“TheraKine”) in order to explore potential business opportunities to exploit TheraKine's drug delivery technologies. TheraKine is the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before. During the year ended March 31, 2015, the Company paid and expensed $ 20,000

Going Concern

Going Concern	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Going Concern [Abstract]
Going Concern	Note 2. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended December 31, 2015, the Company had a net loss of $676,512 and negative cash flow from operating activities of $454,830. As of December 31, 2015, the Company had negative working capital of $518,425. Management does not anticipate having positive cash flow from operations in the near future. These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company does not have the resources at this time to repay its credit and debt obligations, make any payments in the form of dividends to its shareholders or implement its business plan. Without additional capital, the Company will not be able to remain in business. Management has plans to address the Company’s financial situation as follows: In the near term, management plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern. In the long term, management believes that the Company’s projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company’s future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.	Note 2. Going Concern For the fiscal year ended March 31, 2015, the Company had a net loss of $ 990,233 371,810 446,218 These factors raise a substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company does not have the resources at this time to repay its credit and debt obligations, make any payments in the form of dividends to its shareholders or fully implement its business plan. Without additional capital, the Company will not be able to remain in business. Management has plans to address the Company's financial situation as follows: In the near term, management plans to continue to focus on raising the funds necessary to implement the Company's business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company's financial obligations. There is no assurance, however, that lenders will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raises doubts about the Company's ability to continue as a going concern. In the long term, management believes that the Company's projects and initiatives will be successful and will provide cash flow to the Company that will be used to finance the Company's future growth. However, there can be no assurances that the Company's planned activities will be successful, or that the Company will ultimately attain profitability. The Company's long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies Interim Financial Statements The accompanying these unaudited financial statements have been prepared in accordance with accounting principles generally accepted accounting in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended March 31, 2015 and notes thereto and other pertinent information contained in our Form 10-K the Company has filed with the Securities and Exchange Commission (the “SEC”). The results of operations for the nine month period ended December 31, 2015 are not necessarily indicative of the results to be expected for the full fiscal year ending March 31, 2016. Basis of Presentation The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The financial statements have been prepared using the accrual basis of accounting in accordance with GAAP. Principles of Consolidation The consolidated financial statements include the accounts and operations of Rainbow Coral Corp., and its wholly owned subsidiaries, Rainbow Biosciences, LLC and Father Fish Aquarium, Inc. (collectively referred to as the “Company”). All material intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Related Parties The Company follows ASC 850, Related Party Disclosures Recently Issued Accounting Pronouncements We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.	Note 3. Significant Accounting Policies Basis of Presentation The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The financial statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Principles of Consolidation The consolidated financial statements include the accounts and operations of Rainbow Coral Corp., and its wholly owned subsidiaries, Rainbow Biosciences, LLC and Father Fish Aquarium, Inc. (collectively referred to as the “Company”). All material intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For the purpose of the financial statements, cash equivalents include all highly liquid investments with maturity of three months or less. Cash and cash equivalents were $ 5,180 65,373 Inventory Inventory consists of aquarium products and other pet supply items valued at the lower of cost or net realizable value determined using the weighted average cost method, and with market defined as the lower of replacement cost or realizable value. The cost of inventory includes all costs to purchase, costs of conversion and other costs incurred in bringing the inventory to its present location and condition. Inventory is reduced for the estimated losses due to obsolescence. Fixed Assets Our fixed assets consist of vehicles and computer equipment, which are stated at cost. Expenditures for fixed assets that substantially increase the useful lives of existing assets are capitalized at cost and depreciated. Routine expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided principally on the straight-line method over the estimated useful lives of three to five years for financial reporting purposes. Impairment of long-lived assets Long-lived assets, including fixed assets and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If it is determined that an impairment loss has occurred, the loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company determined that there was no impairment of long-lived assets during the year ended March 31, 2015. Revenue and cost recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is generated from the sales of live coral and other related products in a retail setting. Revenue is recognized net of sales returns and allowances. Costs of goods sold represents product costs associated with generating revenue. It includes all costs of purchase, costs of conversion and other costs of acquiring products that have been sold. Advertising Costs The Company's policy regarding advertising is to expense advertising costs as incurred. The Company incurred $ 3,832 23,239 Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes Earnings (Loss) per Common Share The Company computes basic and diluted earnings per common share amounts in accordance with ASC Topic 260, Earnings per Share . The basic earnings (loss) per common share are calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. There are no dilutive shares outstanding for any periods reported. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The Company's convertible debt is considered anti-dilutive due to the Company's net loss for the years ended March 31, 2015 and 2014. As a result, the Company did not have any potentially dilutive common shares for those periods. For the year ended March 31, 2015 and 2014, potentially issuable shares as a result of conversions of convertible notes payable have been excluded from the calculation. At March 31, 2015, the Company had 27,458,608 Financial Instruments The Company's balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable, and accrued expenses. The fair value of the Company's notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value. Subsequent events The Company evaluated material events occurring between the end of our fiscal year, March 31, 2015, and through the date when the consolidated financial statements were available to be issued for disclosure consideration. Recently Issued Accounting Pronouncements Recently issued accounting pronouncements are not expected to, or did not have, a material impact on our financial position, results of operations or cash flows.

Advances

Advances	12 Months Ended
	Mar. 31, 2015
Short-term Debt [Abstract]
Advances	Note 4. Advances During the year ended March 31, 2015, Vista View Ventures, Inc. advanced $ 276,822 426,275 0 149,453

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Convertible Notes Payable [Abstract]
Convertible Notes Payable	Note 4. Convertible Notes Payable During the nine months ended December 31, 2015, Vista View Ventures, Inc. (“Vista View”) advanced $423,909 to the Company for working capital. Vista View paid the advances to KMDA, and subsequently KMDA paid them to the Company on behalf of Vista View. These advances are typically memorialized into a convertible note payable on a quarterly basis as discussed below. Convertible notes payable consist of the following as of December 31, 2015 and March 31, 2015: December 31, 2015 March 31, 2015 Convertible note dated June 30, 2014, bearing interest at 10% per annum, maturing June 30, 2016 and convertible into shares of common stock at $0.02 per share 2,322 62,980 Convertible note dated September 30, 2014, bearing interest at 10% per annum, maturing September 30, 2016 and convertible into shares of common stock at $0.01 per share 80,133 80,133 Convertible note dated December 31, 2014, bearing interest at 10% per annum, maturing December 31, 2016 and convertible into shares of common stock at $0.01 per share 94,074 94,074 Convertible note dated December 31, 2014, bearing interest at 10% per annum, maturing December 31, 2016 and convertible into shares of common stock at $0.02 per share. — 125,059 Convertible note dated March 31, 2015, bearing interest at 10% per annum, maturing March 31, 2017 and convertible into shares of common stock at $0.007 per share 39,635 39,635 Convertible note dated June 30, 2015, bearing interest at 10% per annum, maturing June 30, 2017 and convertible into shares of common stock at $0.25 per share. 54,006 — Convertible note dated September 30, 2015, bearing interest at 10% per annum, maturing September 30, 2018, and convertible into shares of common stock at $0.25 per share. 267,558 — Convertible note dated December 31, 2015, bearing interest at 10% per annum, maturing December 31, 2018 and convertible into shares of common stock at $0.09 per share 102,345 — Total convertible notes payable $ 640,073 $ 401,881 Less: current portion of convertible notes payable (176,529 ) — Less: discount on convertible notes payable (449,371 ) (237,643 ) Convertible notes payable, net of discount $ 14,173 $ 164,238 Current portion of convertible notes payable 176,529 — Less: discount on current portion of convertible notes payable (116,664 ) — Current portion of convertible notes payable, net of discount $ 59,865 $ — Convertible notes issued During the nine months ended December 31, 2015, the Company signed Convertible Promissory Notes totaling $423,909 with Vista View Ventures, Inc. that memorialize non-interest bearing periodic advances into convertible notes payable. The Convertible Promissory Notes bear interest at 10% per annum and are payable along with accrued interest at maturity. The Convertible Promissory Note and unpaid accrued interest are convertible into common stock at the option of the holder. The holder of the notes may not convert the convertible promissory note into common stock if that conversion would result in the holder owning more than 4.99% of the Company’s outstanding common stock on the conversion date. Date Issued Maturity Date Interest Rate Conversion Rate Note Amount June 30, 2015 June 30, 2017 10% $ 0.25 $ 54,006 September 30, 2015 September 30, 2018 10% 0.25 267,558 December 31, 2015 December 31, 2018 10% 0.09 102,345 Total $ 423,909 The Company evaluated the terms of the notes in accordance with ASC Topic No. 815 – 40, Derivatives and Hedging - Contracts in Entity’s Own Stock Conversions to Common Stock During the nine months ended December 31, 2015, Essen Enterprises, Inc. (“Essen”), the original payee of the Convertible Note Payable dated December 31, 2014 elected to convert principal and accrued interest in the amounts show below into share of common stock at a rate of $0.02 per share. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement that provided for conversion. Date Amount Converted Shares of Common Stock Issued June 1, 2015 $ 130,267 6,513,344 Total $ 130,267 6,513,344 As a result of this conversion, Essen became a significant shareholder of the Company. During the nine months ended December 31, 2015, the holders of the Convertible Note Payable dated June 30, 2014 elected to convert principal and accrued interest in the amounts show below into share of common stock at a rate of $0.02 per share. On the conversion date, the unamortized discount related to the principal amount converted was immediately amortized to interest expense. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement that provided for conversion. Date Amount Converted Shares of Common Stock Issued June 5, 2015 $ 13,600 680,000 July 8, 2015 1,400 70,000 July 16, 2015 7,520 376,000 July 22, 2015 3,220 161,000 July 23, 2015 995 49,750 July 24, 2015 4,920 246,000 August 3, 2015 2,200 110,000 August 11, 2015 3,860 193,000 August 18, 2015 2,040 102,000 August 26, 2015 4,280 214,000 September 11, 2015 5,560 278,000 September 24, 2015 4,000 200,000 September 29, 2015 7,449 372,450 October 1, 2015 5,940 297,000 October 8, 2015 789 39,450 Total $ 67,773 3,388,650 During the nine months ended December 31, 2015, the holders of the Convertible Note Payable dated September 30, 2014 elected to convert principal and accrued interest in the amounts show below into share of common stock at a rate of $0.01 per share. On the conversion date, the unamortized discount related to the principal amount converted was immediately amortized to interest expense. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement that provided for conversion. Date Amount Converted Shares of Common Stock Issued December 22, 2015 $ 1,920 192,000 Total $ 1,920 192,000 In connection with the 1 for 100 reverse common stock split on May 29, 2015, the conversion rates of the outstanding convertible notes payable were not modified. As a result, in the event all potentially issuable shares were converted, the holders of the existing notes at December 31, 2015 would be issued 27,841,559 shares of common stock representing approximately 99% of the Company’s total shares outstanding on an if-converted basis. The holders of the notes are limited to holding no greater than 4.99% of the common stock at any time.	Note 5. Convertible Notes Payable Convertible notes payable consist of the following as of March 31, 2015 and March 31, 2014: March 31, 2015 March 31, 2014 Convertible note payable, dated June 30, 2013, bearing interest at 10% per annum, matures on June 30, 2015 and convertible into shares of common stock at $0.04 per share $ — $ 4,742 Convertible note payable, dated September 30, 2013, bearing interest at 10% per annum, matures on September 30, 2015 and convertible into shares of common stock at $0.04 per share — 224,085 Convertible note payable, dated June 30, 2014, bearing interest at 10% per annum, matures on June 30, 2016 and convertible into shares of common stock at $0.02 per share 62,980 — Convertible note payable, dated September 30, 2014, bearing interest at 10% per annum, matures on September 30, 2016 and convertible into shares of common stock at $0.01 per share 80,133 — Convertible note payable, dated December 31, 2014, bearing interest at 10% per annum, matures on December 31, 2016 and convertible into shares of common stock at $0.01 per share 94,074 — Convertible note payable, dated December 31, 2014, bearing interest at 10% per annum, matures on December 31, 2016 and convertible into shares of common stock at $0.02 per share 125,059 — Convertible note payable, dated March 31, 2015, bearing interest at 10% per annum, matures on March 31, 2017 and convertible into shares of common stock at $0.007 per share 39,635 — Total convertible notes payable $ 401,881 $ 228,827 Less: discount on convertible notes payable (237,643 ) (215,716 ) Convertible notes payable, net of discount $ 164,238 $ 13,111 Convertible notes issued During the year ended March 31, 2015, the Company entered into convertible promissory notes with Vista View Ventures, Inc., which refinanced non-interest bearing advances. The convertible notes have the following terms: Date Issued Maturity Date Interest Conversion Amount of April 1, 2014 March 31, 2016 10 % $ 0.03 $ 149,453 June 30, 2014 June 30, 2016 10 % $ 0.02 62,980 September 30, 2014 September 30, 2016 10 % $ 0.01 80,133 December 31, 2014 December 31, 2016 10 % $ 0.01 94,074 December 31, 2014 December 31, 2016 10 % $ 0.02 125,059 March 31, 2015 March 31, 2017 10 % $ 0.007 39,635 Total $ 551,334 All principal along with accrued interest is payable on the maturity date. The Company evaluated the terms of the notes in accordance with ASC Topic No. 815 – 40, Derivatives and Hedging - Contracts in Entity’s Own Stock Conversions to common stock During the year ended March 31, 2015, the holder of the convertible note payable dated June 30, 2013 elected to convert principal and accrued interest in the amounts shown below into shares of common stock at a rate of $0.04 per share. On the conversion date, the unamortized discount related to the principal amount was immediately amortized to interest expense. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement. Date Amount Converted Shares of Common Stock Issued August 20, 2014 $ 4,954 1,239 Total $ 4,954 1,239 During the year ended March 31, 2015, the holder of the convertible note payable dated September 30, 2013 elected to convert principal and accrued interest in the amounts shown below into shares of common stock at a rate of $0.04 per share. On the conversion date, the unamortized discount related to the principal amount was immediately amortized to interest expense. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement. Date Amount Converted Shares of Common Stock Issued April 21, 2014 $ 80,000 20,000 May 14, 2014 40,000 10,000 May 23, 2014 40,000 10,000 June 14, 2014 40,000 10,000 June 18, 2014 38,368 9,592 Total $ 238,368 59,592 During the year ended March 31, 2015, the holder of the Convertible Note Payable dated April 1, 2014 elected to convert principal and accrued interest in the amounts shown below into shares of common stock at a rate of $0.03 per share. On the conversion date, the unamortized discount related to the principal amount was immediately amortized to interest expense. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement. Date Amount Converted Shares of Common Stock Issued October 8, 2014 $ 42,000 14,000 October 9, 2014 42,000 14,000 October 22, 2014 42,000 14,000 January 15, 2015 32,260 10,754 Total $ 158,260 52,754 In connection with the 1 for 100 reverse common stock split on May 29, 2015, the conversion rates of the outstanding convertible notes payable were not modified. As a result, in the event all potentially issuable shares were converted, the holders of the existing notes at March 31, 2015 would be issued 27,458,608 shares of common stock representing approximately 99% of the Company’s total shares outstanding on an if-converted basis. The holders of the notes are limited to holding no greater than 4.99% of the common stock at any time.

Long Term Notes payable

Long Term Notes payable	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Notes Payable, Noncurrent [Abstract]
Notes payable	Note 5. Long-term Notes Payable On December 30, 2013, we entered into a promissory note for $50,000 with a third party bearing interest at 5% per annum. Under the terms of the note payable, the Company is required to pay the note payable beginning on January 1, 2015 and over a period of 4 years. At December 31, 2015 and March 31, 2015, we owed the noteholder $41,280 and $48,150, respectively. During the year ended March 31, 2015, we entered into a promissory note for $5,000 with a third party bearing interest at 5% per annum. Under the terms of the note payable, we are required to repay the note in twenty-six equal monthly installments beginning October 2014. At December 31, 2015 and March 31, 2015, we owed the noteholder $844 and $2,936, respectively.	Note 6. Long Term Notes Payable On December 30, 2013, the Company entered into a promissory note for $ 50,000 5 January 1, 2015 4 48,150 50,000 During the year ended March 31, 2015, the Company entered into a promissory note for $ 5,000 5 twenty-six monthly October 2014 2,936

Debt Payment Obligation

Debt Payment Obligation	12 Months Ended
	Mar. 31, 2015
Debt Payment Obligation [Abstract]
Debt Payment Obligations	Note 7. Debt Payment Obligations The principal due on our convertible notes payable and convertible notes payable is as follows: For the periods ending March 31, 2016 $ 13,734 2017 415,640 2018 13,229 2019 10,364 2020 — Total payments $ 452,967

Related Party Transactions

Related Party Transactions	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 6. Related Party Transactions During the nine months ended December 31, 2015 and 2014, the Company paid consulting fees of $47,115 and $49,500, respectively, to Kimberly Palmer for her services as CEO of the Company. During the nine months ended December 31, 2015, Mr. Foxwell, the president of Father Fish, advanced $35,791 to our subsidiary, Father Fish, for working capital. As of December 31, 2015 and March 31, 2015, related party advances payable to Mr. Foxwell totaled $201,005 and $165,214, respectively. The advances bear no interest and are due on demand. On July 22, 2015, we issued 1,000,000 shares of Series E Preferred stock to Essen Enterprises. See Note 7. Services Provided by KM Delaney & Assoc. During the nine months ended December 31, 2015 and 2014, KM Delaney & Assoc. (“KMDA”) has provided office space and certain administrative functions to us. The services provide include a furnished executive suite, use of office equipment and supplies, accounting and bookkeeping services, treasury and cash management services, financial reporting, and other support staffing requirements. As part of the services provided to the Company, KMDA receives the advances from the lender (See note 4.) and disburses those funds to us. During the nine months ended December 31, 2015 and 2014, KMDA billed us $142,881 and us $127,264, respectively, for those services. As of December 31, 2015 and March 31, 2015, we owed KMDA $174,760 and $245,365, respectively. These amounts are included in accounts payable and accrued liabilities on the balance sheet.	Note 8. Related Party Transactions During the years ended March 31, 2015 and 2014, Mr. Foxwell, the president of Father Fish, advanced $ 33,709 38,442 165,214 131,505

Stockholders' Equity

Stockholders' Equity	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Deficit	Note 7. Stockholders’ Equity On May 29, 2015, the Company reincorporated from Florida to Nevada. The Company’s board of directors and majority shareholder consented to the reincorporation. Each of our shareholders on the record date received one share of the Nevada Company’s common stock for each 100 shares of common stock they own in the Florida company. The information contained herein gives retroactive effect to the stock split for all periods presented. Fractional shares were rounded up to the next whole share, and each shareholder received at least five shares. Following the reincorporation, the Company is authorized to issue 500 million shares of common stock and 20 million shares of preferred stock, each with a par value of $0.001 per share. At December 31, 2015, the Company had 26,014,935 potentially issuable common shares with exercise prices ranging from $0.09 per share to $0.25 per share. The exercise prices of the convertible debt were not modified as a result of the reincorporation and the stock split. See Note 5. Preferred Stock On July 22, 2015, we issued 1,000,000 shares of Series E Preferred stock to Essen Enterprises, Inc (“Essen”). The beneficial owner of Essen is Filipp Korolev. On that date, Essen owned 6,513,344 shares of our common stock, which constituted 63.55% of our outstanding common shares. The Series E Preferred stock is subordinate to our common stock and does not participate in dividends or equity distributions. The Series E preferred stock has ⅔ voting control of the company. The shares were issued so that Essen could retain stable control of the Company, which could have been lost as a result of expected issuance of common stocks resulting from conversion of our convertible notes. These shares were valued at $140,000 which was the estimated market value of the Series E Preferred Stock on the date of the transaction. The market value was determined by estimating the market value of the controlling interest in a public company. Conversion of shares During the nine months ended December 31, 2015, the holders of our convertible notes elected to convert principal and accrued interest of $199,959 into 10,093,994 shares of common stock.	Note 9. Stockholders' Equity On May 29, 2015, the Company reincorporated from Florida to Nevada. The Company's board of directors and majority shareholder consented to the reincorporation. Each of our shareholders on the record date received one share of the Nevada Company's common stock for each 100 shares of common stock they own in the Florida company. The information contained herein gives retroactive effect to the stock split for all periods presented. Fractional shares were rounded up to the next whole share, and each shareholder received at least five shares. Following the reincorporation, the Company is authorized to issue 480 20 0.001 At March 31, 2015, the Company had 27,458,608 0.007 0.02 0.01 During year ended March 31, 2015, the holders of our convertible notes elected to convert principal and interest of $ 401,582 113,585

Commitments

Commitments	12 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments	Note 10. Commitments The Company has an arrangement with a third party whereby the third party provides the Company with office space, legal services, accounting services, fundraising and management services. During the year ended March 31, 2015, the Company incurred $200,383 of fees related to the third party. At March 31, 2015, The Company owed the third party $172,246, which is recorded in accounts payable and accrued expenses.

Business Segments

Business Segments	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Segment Reporting [Abstract]
Business Segments	Note 8. Business Segments The Company has two reportable operating segments: (1) aquarium and aquarium supplies and (2) medical technology. These reportable segments are managed separately due to differences in their products. The only segment that generates revenue is aquarium and aquarium supplies. Management evaluates and monitors performance of this segment primarily through, among other measures, gross profit. The medical technology segment is in the development stage and not begun to generate revenue. The results of operations and financial position of the two reportable operating segments and corporate were as follows: Results of Operations: Nine months ended December 31, Three months ended December 31, 2015 2014 2015 2014 REVENUE Aquarium and aquarium supplies $ 84,387 $ 99,503 $ 28,040 $ 28,182 Medical technology — — — — Corporate — — — — $ 84,387 $ 99,503 $ 28,040 $ 28,182 GROSS PROFIT Aquarium and aquarium supplies $ 50,290 $ 51,176 $ 18,857 $ 17,590 Medical technology — — — — Corporate — — — — $ 50,290 51,176 $ 18,857 17,590 GENERAL AND ADMINISTRATIVE EXPENSE Aquarium and aquarium supplies $ 72,827 $ 83,376 $ 25,254 $ 23,902 Medical technology 15,000 70,000 — 10,000 Corporate 510,987 324,768 131,795 113,311 $ 598,814 $ 478,144 $ 157,049 $ 147,213 Corporate operating expense includes general and administrative costs not allocated to operating segments. December 31, 2015 March 31, 2015 TOTAL ASSETS Aquarium and aquarium supplies $ 5,528 $ 6,800 Medical technology — — Corporate 1,166 4,528 $ 6,694 $ 11,328	Note 11. Business Segments The Company has two reportable operating segments: (1) aquarium and aquarium supplies and (2) medical technology. These reportable segments are financed and managed separately due to differences in their products and overall business plan. The only segment that generates revenue is aquarium and aquarium supplies. Management evaluates and monitors performance of this segment primarily through, among other measures, gross profit. The medical technology segment is in the development stage and not begun to generate revenue. The results of operations and financial position of the two reportable operating segments and corporate were as follows: Results of Operations: Year ended March 31, 2015 2014 REVENUE Aquarium and aquarium supplies $ 128,133 $ 113,009 Medical technology — — Corporate — — $ 128,133 $ 113,009 GROSS PROFIT (LOSS) Aquarium and aquarium supplies $ 58,388 $ (219 ) Medical technology — — Corporate — — $ 58,388 (219 ) OPERATING EXPENSES Aquarium and aquarium supplies $ 103,091 $ 144,788 Medical technology 80,000 85,000 Corporate 461,296 440,111 $ 644,387 $ 669,899 Corporate operating expense includes general and administrative costs not allocated to operating segments. March 31, 2015 March 31, 2014 TOTAL ASSETS Aquarium and aquarium supplies $ 6,800 $ 24,756 Medical technology — — Corporate 4,528 52,989 $ 11,328 $ 77,745

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes There is no current or deferred income tax expense or benefit for the period ended March 31, 2015. The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference for the periods ended March 31, 2015 and 2014 are as follows. 2015 2014 Tax benefit at U.S. statutory rate $ 337,000 $ 370,000 Amortization of discount on convertible notes payable (136,000 ) (160,000 ) Changes in valuation allowance (201,000 ) (210,000 ) $ — $ —

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 9. Subsequent Events The Company evaluated material events occurring between the end of our fiscal year, March 31, 2016, and through the date when the consolidated financial statements were available to be issued for disclosure consideration. On January 20, 2016, the holders of the convertible promissory note dated June 30, 2014 converted $2,388 of principal and accrued interest into 119,418 shares of common stock.	Note 13. Subsequent Events On May 29, 2015 Nevada On June 1, 2015 125,059 130,267 6,513,344 On June 6, 2015 62,980 13,600 680,000

Significant Accounting Polici20

Significant Accounting Policies (Policy)	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The financial statements have been prepared using the accrual basis of accounting in accordance with GAAP.	Basis of Presentation The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The financial statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Interim Financial Statements	Interim Financial Statements The accompanying these unaudited financial statements have been prepared in accordance with accounting principles generally accepted accounting in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended March 31, 2015 and notes thereto and other pertinent information contained in our Form 10-K the Company has filed with the Securities and Exchange Commission (the “SEC”). The results of operations for the nine month period ended December 31, 2015 are not necessarily indicative of the results to be expected for the full fiscal year ending March 31, 2016.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts and operations of Rainbow Coral Corp., and its wholly owned subsidiaries, Rainbow Biosciences, LLC and Father Fish Aquarium, Inc. (collectively referred to as the “Company”). All material intercompany accounts and transactions have been eliminated in consolidation.	Principles of Consolidation The consolidated financial statements include the accounts and operations of Rainbow Coral Corp., and its wholly owned subsidiaries, Rainbow Biosciences, LLC and Father Fish Aquarium, Inc. (collectively referred to as the “Company”). All material intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents		Cash and Cash Equivalents For the purpose of the financial statements, cash equivalents include all highly liquid investments with maturity of three months or less. Cash and cash equivalents were $ 5,180 65,373
Inventory		Inventory Inventory consists of aquarium products and other pet supply items valued at the lower of cost or net realizable value determined using the weighted average cost method, and with market defined as the lower of replacement cost or realizable value. The cost of inventory includes all costs to purchase, costs of conversion and other costs incurred in bringing the inventory to its present location and condition. Inventory is reduced for the estimated losses due to obsolescence.
Fixed Assets		Fixed Assets Our fixed assets consist of vehicles and computer equipment, which are stated at cost. Expenditures for fixed assets that substantially increase the useful lives of existing assets are capitalized at cost and depreciated. Routine expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided principally on the straight-line method over the estimated useful lives of three to five years for financial reporting purposes.
Impairment of Long-Lived Assets		Impairment of long-lived assets Long-lived assets, including fixed assets and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If it is determined that an impairment loss has occurred, the loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company determined that there was no impairment of long-lived assets during the year ended March 31, 2015.
Revenue and Cost Recognition		Revenue and cost recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is generated from the sales of live coral and other related products in a retail setting. Revenue is recognized net of sales returns and allowances. Costs of goods sold represents product costs associated with generating revenue. It includes all costs of purchase, costs of conversion and other costs of acquiring products that have been sold.
Advertising Costs		Advertising Costs The Company's policy regarding advertising is to expense advertising costs as incurred. The Company incurred $ 3,832 23,239
Income Taxes		Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes
Earnings (Loss) per Common Share
Financial Instruments		Financial Instruments The Company's balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable, and accrued expenses. The fair value of the Company's notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value.
Subsequent events		Subsequent events The Company evaluated material events occurring between the end of our fiscal year, March 31, 2015, and through the date when the consolidated financial statements were available to be issued for disclosure consideration.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.	Recently Issued Accounting Pronouncements Recently issued accounting pronouncements are not expected to, or did not have, a material impact on our financial position, results of operations or cash flows.
Related Parties	Related Parties The Company follows ASC 850, Related Party Disclosures

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Convertible Notes Payable [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consist of the following as of December 31, 2015 and March 31, 2015: December 31, 2015 March 31, 2015 Convertible note dated June 30, 2014, bearing interest at 10% per annum, maturing June 30, 2016 and convertible into shares of common stock at $0.02 per share 2,322 62,980 Convertible note dated September 30, 2014, bearing interest at 10% per annum, maturing September 30, 2016 and convertible into shares of common stock at $0.01 per share 80,133 80,133 Convertible note dated December 31, 2014, bearing interest at 10% per annum, maturing December 31, 2016 and convertible into shares of common stock at $0.01 per share 94,074 94,074 Convertible note dated December 31, 2014, bearing interest at 10% per annum, maturing December 31, 2016 and convertible into shares of common stock at $0.02 per share. — 125,059 Convertible note dated March 31, 2015, bearing interest at 10% per annum, maturing March 31, 2017 and convertible into shares of common stock at $0.007 per share 39,635 39,635 Convertible note dated June 30, 2015, bearing interest at 10% per annum, maturing June 30, 2017 and convertible into shares of common stock at $0.25 per share. 54,006 — Convertible note dated September 30, 2015, bearing interest at 10% per annum, maturing September 30, 2018, and convertible into shares of common stock at $0.25 per share. 267,558 — Convertible note dated December 31, 2015, bearing interest at 10% per annum, maturing December 31, 2018 and convertible into shares of common stock at $0.09 per share 102,345 — Total convertible notes payable $ 640,073 $ 401,881 Less: current portion of convertible notes payable (176,529 ) — Less: discount on convertible notes payable (449,371 ) (237,643 ) Convertible notes payable, net of discount $ 14,173 $ 164,238 Current portion of convertible notes payable 176,529 — Less: discount on current portion of convertible notes payable (116,664 ) — Current portion of convertible notes payable, net of discount $ 59,865 $ —	Convertible notes payable consist of the following as of March 31, 2015 and March 31, 2014: March 31, 2015 March 31, 2014 Convertible note payable, dated June 30, 2013, bearing interest at 10% per annum, matures on June 30, 2015 and convertible into shares of common stock at $0.04 per share $ — $ 4,742 Convertible note payable, dated September 30, 2013, bearing interest at 10% per annum, matures on September 30, 2015 and convertible into shares of common stock at $0.04 per share — 224,085 Convertible note payable, dated June 30, 2014, bearing interest at 10% per annum, matures on June 30, 2016 and convertible into shares of common stock at $0.02 per share 62,980 — Convertible note payable, dated September 30, 2014, bearing interest at 10% per annum, matures on September 30, 2016 and convertible into shares of common stock at $0.01 per share 80,133 — Convertible note payable, dated December 31, 2014, bearing interest at 10% per annum, matures on December 31, 2016 and convertible into shares of common stock at $0.01 per share 94,074 — Convertible note payable, dated December 31, 2014, bearing interest at 10% per annum, matures on December 31, 2016 and convertible into shares of common stock at $0.02 per share 125,059 — Convertible note payable, dated March 31, 2015, bearing interest at 10% per annum, matures on March 31, 2017 and convertible into shares of common stock at $0.007 per share 39,635 — Total convertible notes payable $ 401,881 $ 228,827 Less: discount on convertible notes payable (237,643 ) (215,716 ) Convertible notes payable, net of discount $ 164,238 $ 13,111
Schedule of Convertible Notes Issued	Date Issued Maturity Date Interest Rate Conversion Rate Note Amount June 30, 2015 June 30, 2017 10% $ 0.25 $ 54,006 September 30, 2015 September 30, 2018 10% 0.25 267,558 December 31, 2015 December 31, 2018 10% 0.09 102,345 Total $ 423,909	Date Issued Maturity Date Interest Conversion Amount of April 1, 2014 March 31, 2016 10 % $ 0.03 $ 149,453 June 30, 2014 June 30, 2016 10 % $ 0.02 62,980 September 30, 2014 September 30, 2016 10 % $ 0.01 80,133 December 31, 2014 December 31, 2016 10 % $ 0.01 94,074 December 31, 2014 December 31, 2016 10 % $ 0.02 125,059 March 31, 2015 March 31, 2017 10 % $ 0.007 39,635 Total $ 551,334
Schedule of Conversions To Common Stock	Date Amount Converted Shares of Common Stock Issued June 1, 2015 $ 130,267 6,513,344 Total $ 130,267 6,513,344 Date Amount Converted Shares of Common Stock Issued June 5, 2015 $ 13,600 680,000 July 8, 2015 1,400 70,000 July 16, 2015 7,520 376,000 July 22, 2015 3,220 161,000 July 23, 2015 995 49,750 July 24, 2015 4,920 246,000 August 3, 2015 2,200 110,000 August 11, 2015 3,860 193,000 August 18, 2015 2,040 102,000 August 26, 2015 4,280 214,000 September 11, 2015 5,560 278,000 September 24, 2015 4,000 200,000 September 29, 2015 7,449 372,450 October 1, 2015 5,940 297,000 October 8, 2015 789 39,450 Total $ 67,773 3,388,650 Date Amount Converted Shares of Common Stock Issued December 22, 2015 $ 1,920 192,000 Total $ 1,920 192,000	Date Amount Converted Shares of Common Stock Issued August 20, 2014 $ 4,954 1,239 Total $ 4,954 1,239 Date Amount Converted Shares of Common Stock Issued April 21, 2014 $ 80,000 20,000 May 14, 2014 40,000 10,000 May 23, 2014 40,000 10,000 June 14, 2014 40,000 10,000 June 18, 2014 38,368 9,592 Total $ 238,368 59,592 Date Amount Converted Shares of Common Stock Issued October 8, 2014 $ 42,000 14,000 October 9, 2014 42,000 14,000 October 22, 2014 42,000 14,000 January 15, 2015 32,260 10,754 Total $ 158,260 52,754

Debt Payment Obligations (Table

Debt Payment Obligations (Tables)	12 Months Ended
	Mar. 31, 2015
Debt Payment Obligation [Abstract]
Debt Payment Obligations	For the periods ending March 31, 2016 $ 13,734 2017 415,640 2018 13,229 2019 10,364 2020 — Total payments $ 452,967

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of Results of Operations by Reporting Segment	The results of operations and financial position of the two reportable operating segments and corporate were as follows: Results of Operations: Nine months ended December 31, Three months ended December 31, 2015 2014 2015 2014 REVENUE Aquarium and aquarium supplies $ 84,387 $ 99,503 $ 28,040 $ 28,182 Medical technology — — — — Corporate — — — — $ 84,387 $ 99,503 $ 28,040 $ 28,182 GROSS PROFIT Aquarium and aquarium supplies $ 50,290 $ 51,176 $ 18,857 $ 17,590 Medical technology — — — — Corporate — — — — $ 50,290 51,176 $ 18,857 17,590 GENERAL AND ADMINISTRATIVE EXPENSE Aquarium and aquarium supplies $ 72,827 $ 83,376 $ 25,254 $ 23,902 Medical technology 15,000 70,000 — 10,000 Corporate 510,987 324,768 131,795 113,311 $ 598,814 $ 478,144 $ 157,049 $ 147,213	Results of Operations: Year ended March 31, 2015 2014 REVENUE Aquarium and aquarium supplies $ 128,133 $ 113,009 Medical technology — — Corporate — — $ 128,133 $ 113,009 GROSS PROFIT (LOSS) Aquarium and aquarium supplies $ 58,388 $ (219 ) Medical technology — — Corporate — — $ 58,388 (219 ) OPERATING EXPENSES Aquarium and aquarium supplies $ 103,091 $ 144,788 Medical technology 80,000 85,000 Corporate 461,296 440,111 $ 644,387 $ 669,899 Corporate operating expense includes general and administrative costs not allocated to operating segments. March 31, 2015 March 31, 2014 TOTAL ASSETS Aquarium and aquarium supplies $ 6,800 $ 24,756 Medical technology — — Corporate 4,528 52,989 $ 11,328 $ 77,745
Schedule of corporate operating expense	Corporate operating expense includes general and administrative costs not allocated to operating segments. December 31, 2015 March 31, 2015 TOTAL ASSETS Aquarium and aquarium supplies $ 5,528 $ 6,800 Medical technology — — Corporate 1,166 4,528 $ 6,694 $ 11,328

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Income Tax Rate Reconciliation	2015 2014 Tax benefit at U.S. statutory rate $ 337,000 $ 370,000 Amortization of discount on convertible notes payable (136,000 ) (160,000 ) Changes in valuation allowance (201,000 ) (210,000 ) $ — $ —

Background Information (Details

Background Information (Details)	May. 29, 2015$ / sharesshares	Dec. 31, 2015$ / sharesshares	Mar. 31, 2015$ / sharesshares	Mar. 31, 2014$ / sharesshares
Class of Stock [Line Items]
Common Stock, par value per share | $ / shares	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common Stock, shares authorized | shares	500,000,000	480,000,000	480,000,000	480,000,000
Preferred Stock, par value per share | $ / shares	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, shares authorized | shares	20,000,000	20,000,000	20,000,000	20,000,000
Subsequent Event [Member]
Class of Stock [Line Items]
Common Stock, par value per share | $ / shares	$ 0.001
Common Stock, shares authorized | shares	480,000,000
Preferred Stock, par value per share | $ / shares	$ 0.001
Preferred Stock, shares authorized | shares	20,000,000
Reverse stock split ratio	0.01
Reincorporation, state	Nevada
Reincorporation, date	May 29, 2015

Background Information (Joint V

Background Information (Joint Ventures) (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Related Party Transaction [Line Items]
Expenses related to joint ventures and other business development agreements			$ 10,000	$ 15,000	$ 70,000	$ 80,000	$ 85,000
Nano Three Dimensional Biosciences Inc Joint Venture [Member]
Related Party Transaction [Line Items]
Shares acquired of joint venture's common stock	145
Payments to joint venture	$ 60,000
Expenses related to joint ventures and other business development agreements						60,000
Nano Three Dimensional Biosciences Inc Joint Venture [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Shares acquired of joint venture's common stock	604
Percentage of outstanding stock acquired	5.00%
Common stock, price per share	$ 413.62
Payments to joint venture	$ 249,826
Weekly payments to joint venture	$ 5,000
Therakine Ltd Joint Venture [Member]
Related Party Transaction [Line Items]
Expenses related to joint ventures and other business development agreements						$ 20,000

Going Concern (Details)

Going Concern (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Going Concern [Abstract]
Net loss	$ 179,758	$ 251,481	$ 676,512	$ 787,518	$ 990,233	$ 1,097,141
Net cash used in operating activities			$ 454,830	$ 297,154	371,810	$ 531,818
Negative working capital					$ 446,218

Significant Accounting Polici28

Significant Accounting Policies (Narrative) (Details)	12 Months Ended
	Mar. 31, 2015USD ($)shares	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Mar. 31, 2013USD ($)
Accounting Policies [Abstract]
Cash and cash equivalents	$ 5,180	$ 65,373	$ 1,372	$ 31,262	$ 84,592
Advertising costs	$ 3,832	$ 23,239
Potentially issuable shares upon the conversion of convertible notes payable and interest | shares	27,458,608
Commitments and contingencies

Significant Accounting Polici29

Significant Accounting Policies (Fixed Assets) (Details)	12 Months Ended
	Mar. 31, 2015
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	5 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	3 years

Advances (Details)

Advances (Details) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Short-term Debt [Abstract]
Proceeds from advances	$ 423,909	$ 237,187	$ 276,822	$ 432,683
Refinance of advances into convertible notes payable		$ 125,059	$ 426,275	416,685
Advances payable				$ 149,453

Convertible Notes Payable (Sche

Convertible Notes Payable (Schedule of Convertible Notes Payable) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2015	Mar. 31, 2014
Debt Instrument [Line Items]
Convertible notes payable, net of discount	$ 164,238	$ 14,173	$ 13,111
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Total convertible notes payable	401,881		228,827
Less: discount on convertible notes payable	(237,643)		(215,716)
Convertible notes payable, net of discount	164,238		$ 13,111
Convertible Promissory Note Dated September 30, 2014 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Total convertible notes payable	$ 80,133
Debt instrument, issuance date	Sep. 30, 2014
Debt instrument, maturity date	Sep. 30, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.01
Convertible Promissory Note Dated June 30, 2013 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Total convertible notes payable			$ 4,742
Debt instrument, issuance date	Jun. 30, 2013
Debt instrument, maturity date	Jun. 30, 2015
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.04
Convertible Promissory Note Dated April 1, 2014 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date	Apr. 1, 2014
Debt instrument, maturity date	Mar. 31, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.03
Convertible Promissory Note Dated September 30, 2013 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Total convertible notes payable			$ 224,085
Debt instrument, issuance date	Sep. 30, 2013
Debt instrument, maturity date	Sep. 30, 2015
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.04
Convertible Promissory Note Dated June 30, 2014 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Total convertible notes payable	$ 62,980
Debt instrument, issuance date	Jun. 30, 2014
Debt instrument, maturity date	Jun. 30, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.02
Convertible Promissory Note Dated December 31, 2014 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Total convertible notes payable	$ 125,059
Debt instrument, issuance date	Dec. 31, 2014
Debt instrument, maturity date	Dec. 31, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.02
Convertible Promissory Note Dated March 31, 2015 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Total convertible notes payable	$ 39,635
Debt instrument, issuance date	Mar. 31, 2015
Debt instrument, maturity date	Mar. 31, 2017
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.007
Convertible Promissory Note Dated December 31, 2014 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Total convertible notes payable	$ 94,074
Debt instrument, issuance date	Dec. 31, 2014
Debt instrument, maturity date	Dec. 31, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.01

Convertible Notes Payable (Sc32

Convertible Notes Payable (Schedule of Convertible Notes Issued) (Details) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Debt Instrument [Line Items]
Beneficial conversion discount on convertible notes	$ 423,909	$ 360,299	$ 399,935	$ 416,685
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 551,334
Convertible Promissory Note Dated December 31, 2014 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date			Dec. 31, 2014
Debt instrument, maturity date			Dec. 31, 2016
Debt instrument, interest rate			10.00%
Debt instrument, conversion price per share			$ 0.01
Debt instrument, face amount			$ 94,074
Convertible Promissory Note Dated September 30, 2014 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date			Sep. 30, 2014
Debt instrument, maturity date			Sep. 30, 2016
Debt instrument, interest rate			10.00%
Debt instrument, conversion price per share			$ 0.01
Debt instrument, face amount			$ 80,133
Convertible Promissory Note Dated June 30, 2013 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date			Jun. 30, 2013
Debt instrument, maturity date			Jun. 30, 2015
Debt instrument, interest rate			10.00%
Debt instrument, conversion price per share			$ 0.04
Convertible Promissory Note Dated April 1, 2014 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date			Apr. 1, 2014
Debt instrument, maturity date			Mar. 31, 2016
Debt instrument, interest rate			10.00%
Debt instrument, conversion price per share			$ 0.03
Debt instrument, face amount			$ 149,453
Convertible Promissory Note Dated September 30, 2013 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date			Sep. 30, 2013
Debt instrument, maturity date			Sep. 30, 2015
Debt instrument, interest rate			10.00%
Debt instrument, conversion price per share			$ 0.04
Convertible Promissory Note Dated June 30, 2014 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date			Jun. 30, 2014
Debt instrument, maturity date			Jun. 30, 2016
Debt instrument, interest rate			10.00%
Debt instrument, conversion price per share			$ 0.02
Debt instrument, face amount			$ 62,980
Convertible Promissory Note Dated December 31, 2014 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date			Dec. 31, 2014
Debt instrument, maturity date			Dec. 31, 2016
Debt instrument, interest rate			10.00%
Debt instrument, conversion price per share			$ 0.02
Debt instrument, face amount			$ 125,059
Convertible Promissory Note Dated March 31, 2015 [Member] | Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date			Mar. 31, 2015
Debt instrument, maturity date			Mar. 31, 2017
Debt instrument, interest rate			10.00%
Debt instrument, conversion price per share			$ 0.007
Debt instrument, face amount			$ 39,635

Convertible Notes Payable (Conv

Convertible Notes Payable (Conversions to Common Stock) (Details)	Jun. 06, 2015USD ($)shares	May. 29, 2015	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)	Mar. 31, 2015USD ($)shares	Mar. 31, 2014USD ($)
Debt Conversion [Line Items]
Amount Converted | $			$ 199,959	$ 369,322	$ 401,582	$ 446,109
Shares of Common Stock Issued			27,841,559		113,585
Potentially issuable shares upon the conversion of convertible notes payable and interest					27,458,608
Maximum ownership percentage allowed after converting					4.99%
Percentage of the Company's total shares outstanding on an if-converted basis					99.00%
Subsequent Event [Member]
Debt Conversion [Line Items]
Reverse stock split ratio		0.01
Convertible Promissory Note Dated December 31, 2014 [Member] | Subsequent Event [Member]
Debt Conversion [Line Items]
Date	Jun. 1, 2015
Amount Converted | $	$ 130,267
Shares of Common Stock Issued	6,513,344
Convertible Promissory Note Dated June 30, 2014 [Member] | Subsequent Event [Member]
Debt Conversion [Line Items]
Date	Jun. 6, 2015
Amount Converted | $	$ 13,600
Shares of Common Stock Issued	680,000
Convertible Promissory Note Dated September 30, 2013 [Member]
Debt Conversion [Line Items]
Amount Converted | $					$ 238,368
Shares of Common Stock Issued					59,592
Convertible Promissory Note Dated September 30, 2013 [Member] | Debt Conversion May 23, 2014 [Member]
Debt Conversion [Line Items]
Date					May 23, 2014
Amount Converted | $					$ 40,000
Shares of Common Stock Issued					10,000
Convertible Promissory Note Dated September 30, 2013 [Member] | Debt Conversion June 14, 2014 [Member]
Debt Conversion [Line Items]
Date					Jun. 14, 2014
Amount Converted | $					$ 40,000
Shares of Common Stock Issued					10,000
Convertible Promissory Note Dated September 30, 2013 [Member] | Debt Conversion June 18, 2014 [Member]
Debt Conversion [Line Items]
Date					Jun. 18, 2014
Amount Converted | $					$ 38,368
Shares of Common Stock Issued					9,592
Convertible Promissory Note Dated September 30, 2013 [Member] | Debt Conversion May 14, 2014 [Member]
Debt Conversion [Line Items]
Date					May 14, 2014
Amount Converted | $					$ 40,000
Shares of Common Stock Issued					10,000
Convertible Promissory Note Dated September 30, 2013 [Member] | Debt Conversion April 21, 2014 [Member]
Debt Conversion [Line Items]
Date					Apr. 21, 2014
Amount Converted | $					$ 80,000
Shares of Common Stock Issued					20,000
Convertible Promissory Note Dated April 1, 2014 [Member]
Debt Conversion [Line Items]
Amount Converted | $					$ 158,260
Shares of Common Stock Issued					52,754
Convertible Promissory Note Dated April 1, 2014 [Member] | Debt Conversion October 9, 2014 [Member]
Debt Conversion [Line Items]
Date					Oct. 9, 2014
Amount Converted | $					$ 42,000
Shares of Common Stock Issued					14,000
Convertible Promissory Note Dated April 1, 2014 [Member] | Debt Conversion October 22, 2014 [Member]
Debt Conversion [Line Items]
Date					Oct. 22, 2014
Amount Converted | $					$ 42,000
Shares of Common Stock Issued					14,000
Convertible Promissory Note Dated April 1, 2014 [Member] | Debt Conversion January 15, 2014 [Member]
Debt Conversion [Line Items]
Date					Jan. 15, 2015
Amount Converted | $					$ 32,260
Shares of Common Stock Issued					10,754
Convertible Promissory Note Dated April 1, 2014 [Member] | Debt Conversion October 8, 2014 [Member]
Debt Conversion [Line Items]
Date					Oct. 8, 2014
Amount Converted | $					$ 42,000
Shares of Common Stock Issued					14,000
Convertible Promissory Note Dated June 30, 2013 [Member]
Debt Conversion [Line Items]
Amount Converted | $					$ 4,954
Shares of Common Stock Issued					1,239
Convertible Promissory Note Dated June 30, 2013 [Member] | Debt Conversion August 20, 2014 [Member]
Debt Conversion [Line Items]
Date					Aug. 20, 2014
Amount Converted | $					$ 4,954
Shares of Common Stock Issued					1,239

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	9 Months Ended
	Dec. 31, 2015	Mar. 31, 2015	Mar. 31, 2014
Convertible notes payable, net of discount	$ 14,173	$ 164,238	$ 13,111
Less: discount on current portion of convertible notes payable	116,664
Current portion of convertible notes payable, net of discount	$ 59,865
10% Convertible Note Payable Due June 30, 2016 [Member]
Issuance date	Jun. 30, 2014
Conversion price (in dollars per share)	$ 0.02
Total convertible notes payable	$ 2,322
10% Convertible Note Payable Due September 30, 2016 [Member]
Issuance date	Sep. 30, 2014
Conversion price (in dollars per share)	$ 0.01
Total convertible notes payable	$ 80,133	$ 80,133
10% Convertible Note Payable Due December 31, 2016 [Member]
Issuance date	Dec. 31, 2014
Conversion price (in dollars per share)	$ 0.01
Total convertible notes payable	$ 94,074	94,074
10% Convertible Note Payable Due March 31, 2017 [Member]
Issuance date	Mar. 31, 2015
Conversion price (in dollars per share)	$ 0.007
Total convertible notes payable	$ 39,635	39,635
Convertible Notes Payable [Member]
Total convertible notes payable	640,073	$ 401,881
Less: current portion of convertible notes payable	(176,529)
Less: discount on convertible notes payable	(449,371)	$ (237,643)
Convertible notes payable, net of discount	14,173	$ 164,238
Current portion of convertible notes payable	176,529
Less: discount on current portion of convertible notes payable	(116,664)
Current portion of convertible notes payable, net of discount	$ 59,865
Essen Enterprises, Inc. [Member] | 10% Convertible Note Payable Due December 31, 2016 [Member]
Issuance date	Dec. 31, 2014
Conversion price (in dollars per share)	$ 0.02
Total convertible notes payable		$ 125,059
Vista View Ventures, Inc. (Non-Interest Bearing Advances) [Member]
Total convertible notes payable	$ 423,909
Vista View Ventures, Inc. (Non-Interest Bearing Advances) [Member] | 10% Convertible Note Payable Due June 30, 2016 [Member]
Total convertible notes payable		$ 62,980
Vista View Ventures, Inc. (Non-Interest Bearing Advances) [Member] | 10% Convertible Note Payable Due June 30, 2017 [Member]
Issuance date	Jun. 30, 2015
Conversion price (in dollars per share)	$ 0.25
Total convertible notes payable	$ 54,006
Vista View Ventures, Inc. (Non-Interest Bearing Advances) [Member] | 10% Convertible Note Payable Due September 30, 2018 [Member]
Issuance date	Sep. 30, 2015
Conversion price (in dollars per share)	$ 0.25
Total convertible notes payable	$ 267,558
Vista View Ventures, Inc. (Non-Interest Bearing Advances) [Member] | 10% Convertible Note Payable Due December 31, 2018 [Member]
Issuance date	Dec. 31, 2015
Conversion price (in dollars per share)	$ 0.09
Total convertible notes payable	$ 102,345

Convertible Notes Payable (De35

Convertible Notes Payable (Details 1) - Vista View Ventures, Inc. (Non-Interest Bearing Advances) [Member] - USD ($)	9 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Note Amount	$ 423,909
10% Convertible Note Payable Due June 30, 2017 [Member]
Date Issued	Jun. 30, 2015
Conversion Rate (in dollars per share)	$ 0.25
Note Amount	$ 54,006
10% Convertible Note Payable Due September 30, 2018 [Member]
Date Issued	Sep. 30, 2015
Conversion Rate (in dollars per share)	$ 0.25
Note Amount	$ 267,558
10% Convertible Note Payable Due December 31, 2018 [Member]
Date Issued	Dec. 31, 2015
Conversion Rate (in dollars per share)	$ 0.09
Note Amount	$ 102,345

Convertible Notes Payable (De36

Convertible Notes Payable (Details 2) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Amount Converted	$ 199,959	$ 369,322	$ 401,582	$ 446,109
Shares of Common Stock Issued	27,841,559		113,585
Essen Enterprises, Inc. [Member]
Amount Converted	$ 130,267
Shares of Common Stock Issued	6,513,344
Essen Enterprises, Inc. [Member] | 10% Convertible Note Payable Due December 31, 2016 [Member]
Amount Converted	$ 130,267
Shares of Common Stock Issued	6,513,344

Convertible Notes Payable (De37

Convertible Notes Payable (Details 3) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Amount Converted	$ 199,959	$ 369,322	$ 401,582	$ 446,109
Shares of Common Stock Issued	27,841,559		113,585
10% Convertible Note Payable Due June 30, 2016 [Member]
Amount Converted	$ 67,773
Shares of Common Stock Issued	3,388,650
10% Convertible Note Payable Due June 30, 2016 [Member] | June 5, 2015 [Member]
Amount Converted	$ 13,600
Shares of Common Stock Issued	680,000
10% Convertible Note Payable Due June 30, 2016 [Member] | July 8, 2015 [Member]
Amount Converted	$ 1,400
Shares of Common Stock Issued	70,000
10% Convertible Note Payable Due June 30, 2016 [Member] | July 16, 2015 [Member]
Amount Converted	$ 7,520
Shares of Common Stock Issued	376,000
10% Convertible Note Payable Due June 30, 2016 [Member] | July 22, 2015 [Member]
Amount Converted	$ 3,220
Shares of Common Stock Issued	161,000
10% Convertible Note Payable Due June 30, 2016 [Member] | July 23, 2015 [Member]
Amount Converted	$ 995
Shares of Common Stock Issued	49,750
10% Convertible Note Payable Due June 30, 2016 [Member] | July 24, 2015 [Member]
Amount Converted	$ 4,920
Shares of Common Stock Issued	246,000
10% Convertible Note Payable Due June 30, 2016 [Member] | August 3, 2015 [Member]
Amount Converted	$ 2,200
Shares of Common Stock Issued	110,000
10% Convertible Note Payable Due June 30, 2016 [Member] | August 11, 2015 [Member]
Amount Converted	$ 3,860
Shares of Common Stock Issued	193,000
10% Convertible Note Payable Due June 30, 2016 [Member] | August 18, 2015 [Member]
Amount Converted	$ 2,040
Shares of Common Stock Issued	102,000
10% Convertible Note Payable Due June 30, 2016 [Member] | August 26, 2015 [Member]
Amount Converted	$ 4,280
Shares of Common Stock Issued	214,000
10% Convertible Note Payable Due June 30, 2016 [Member] | September 11, 2015 [Member]
Amount Converted	$ 5,560
Shares of Common Stock Issued	278,000
10% Convertible Note Payable Due June 30, 2016 [Member] | September 24, 2015 [Member]
Amount Converted	$ 4,000
Shares of Common Stock Issued	200,000
10% Convertible Note Payable Due June 30, 2016 [Member] | September 29, 2015 [Member]
Amount Converted	$ 7,449
Shares of Common Stock Issued	372,450
10% Convertible Note Payable Due June 30, 2016 [Member] | October 1, 2015 [Member]
Amount Converted	$ 5,940
Shares of Common Stock Issued	297,000
10% Convertible Note Payable Due June 30, 2016 [Member] | October 8, 2015 [Member]
Amount Converted	$ 789
Shares of Common Stock Issued	39,450

Convertible Notes Payable (De38

Convertible Notes Payable (Details 4) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Amount Converted	$ 199,959	$ 369,322	$ 401,582	$ 446,109
Shares of Common Stock Issued	27,841,559		113,585
10% Convertible Note Payable Due September 30, 2016 [Member]
Amount Converted	$ 1,920
Shares of Common Stock Issued	192,000
December 22, 2015 [Member] | 10% Convertible Note Payable Due September 30, 2016 [Member]
Amount Converted	$ 1,920
Shares of Common Stock Issued	192,000

Convertible Notes Payable (De39

Convertible Notes Payable (Details Narrative) - USD ($)	May. 29, 2015	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2015	Jun. 30, 2015
Amortization of debt discount		$ 95,517	$ 343,385	$ 378,008	$ 398,067
Reserve stock split ratio	Each shareholder received one share in the Nevada company for each 100 shares they held in the Florida company. Fractional shares were rounded up, and each shareholder received at least five shares.
Number of common shares issued upon conversion		27,841,559		113,585
Percentage of common stock outstanding		99.00%
Vista View Ventures, Inc. (Non-Interest Bearing Advances) [Member]
Total convertible notes payable		$ 423,909
Maximum percentage of ownership interest		4.99%
Effective interest rate		224.88%				222.23%	277.49%

Long Term Notes payable (Detail

Long Term Notes payable (Details) - Notes Payable, Other Payables [Member] - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Promissory Note Dated December 30, 2013 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 50,000
Debt instrument, interest rate	5.00%
Debt instrument, installment payments start date	Jan. 1, 2015
Debt instrument, repayment term	4 years
Notes payable	$ 48,150	$ 50,000
Promissory Note September 30, 2014 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 5,000
Debt instrument, interest rate	5.00%
Debt instrument, frequency of payment	monthly
Debt instrument, installment payments start date	Oct. 1, 2014
Debt instrument, repayment term	26 months
Notes payable	$ 2,936

Debt Payment Obligations (Detai

Debt Payment Obligations (Details)	Mar. 31, 2015USD ($)
For the periods ending March 31,
2,016	$ 13,734
2,017	415,640
2,018	13,229
2,019	$ 10,364
2,020
Total payments	$ 452,967

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jul. 22, 2015	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Advance from related party		$ 35,791	$ 21,926	$ 33,709	$ 38,442
Advances payable to related party		201,005		165,214	$ 131,505
Kimberly Palmer [Member]
Consulting fees paid		47,115	49,500
Mr. Foxwell [Member]
Advance from related party		35,791
Advances payable to related party		201,005		165,214
KM Delaney & Assoc. [Member]
Advances payable to related party		174,760		$ 245,365
Administrative services		$ 142,881	$ 127,264
Series E Preferred Stock [Member] | Essen Enterprises, Inc. [Member]
Number of shares issued	1,000,000

Stockholders' Equity (Details)

Stockholders' Equity (Details)	Jul. 22, 2015USD ($)shares	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)	Mar. 31, 2015USD ($)shares$ / shares	Mar. 31, 2014USD ($)$ / sharesshares	May. 29, 2015$ / sharesshares
Class of Stock [Line Items]
Common Stock, par value per share | $ / shares			$ 0.001		$ 0.001	$ 0.001	$ 0.001
Common Stock, shares authorized | shares			480,000,000		480,000,000	480,000,000	500,000,000
Preferred Stock, par value per share | $ / shares			$ 0.001		$ 0.001	$ 0.001	$ 0.001
Preferred Stock, shares authorized | shares			20,000,000		20,000,000	20,000,000	20,000,000
Potentially issuable shares upon the conversion of convertible notes payable and interest | shares					27,458,608
Amount Converted | $			$ 199,959	$ 369,322	$ 401,582	$ 446,109
Shares of Common Stock Issued | shares			27,841,559		113,585
Percentage of common stock outstanding			99.00%
Number of shares issued, value | $			$ 140,000
Number of common shares issued upon conversion of convertible notes, value | $		$ 369,322	199,959
Essen Enterprises, Inc. [Member]
Class of Stock [Line Items]
Amount Converted | $			$ 130,267
Shares of Common Stock Issued | shares			6,513,344
Series E Preferred Stock [Member] | Essen Enterprises, Inc. [Member]
Class of Stock [Line Items]
Shares of Common Stock Issued | shares	6,513,344
Percentage of common stock outstanding	63.55%
Number of shares issued | shares	1,000,000
Number of shares issued, value | $	$ 140,000
Prefrred stock voting percentage	Preferred stock has voting control of the company.
Weighted Average [Member]
Class of Stock [Line Items]
Debt instrument, conversion price per share | $ / shares					$ 0.01
Maximum [Member]
Class of Stock [Line Items]
Debt instrument, conversion price per share | $ / shares					0.02
Share price (in dollars per share) | $ / shares			$ 0.25
Minimum [Member]
Class of Stock [Line Items]
Debt instrument, conversion price per share | $ / shares					$ 0.007
Share price (in dollars per share) | $ / shares			$ 0.09
Subsequent Event [Member]
Class of Stock [Line Items]
Common Stock, par value per share | $ / shares							$ 0.001
Common Stock, shares authorized | shares							480,000,000
Preferred Stock, par value per share | $ / shares							$ 0.001
Preferred Stock, shares authorized | shares							20,000,000

Commitments (Details)

Commitments (Details) - An Arrangement With A Third Party [Member]	12 Months Ended
	Mar. 31, 2015USD ($)
Other Commitments [Line Items]
Fees incurred in the period	$ 200,383
Commitments recorded as accounts payable and accrued expenses	$ 172,246

Business Segments (Details Narr

Business Segments (Details Narrative)	9 Months Ended
	Dec. 31, 2015Segments
Segment Reporting [Abstract]
Number of reportable operating segments	2

Business Segments Final (Detail

Business Segments Final (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
REVENUE	$ 28,040	$ 28,182	$ 84,387	$ 99,503	$ 128,133	$ 113,009
GROSS PROFIT	18,857	17,590	50,290	51,176	58,388	(219)
OPERATING EXPENSES	157,049	147,213	598,814	478,144
Aquarium And Aquarium Supplies Segment [Member]
Segment Reporting Information [Line Items]
REVENUE	28,040	28,182	84,387	99,503	128,133	113,009
GROSS PROFIT	18,857	17,590	50,290	51,176	58,388	(219)
OPERATING EXPENSES	$ 25,254	$ 23,902	$ 72,827	$ 83,376	$ 103,091	$ 144,788
Medical Technology Segment [Member]
Segment Reporting Information [Line Items]
REVENUE
GROSS PROFIT
OPERATING EXPENSES		$ 10,000	$ 15,000	$ 70,000	$ 80,000	$ 85,000
Corporate Segment [Member]
Segment Reporting Information [Line Items]
REVENUE
GROSS PROFIT
OPERATING EXPENSES	$ 131,795	$ 113,311	$ 510,987	$ 324,768	$ 461,296	$ 440,111

Business Segments (Details 1)

Business Segments (Details 1) - USD ($)	Dec. 31, 2015	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
TOTAL ASSETS	$ 6,694	$ 11,328	$ 77,745
Aquarium And Aquarium Supplies Segment [Member]
Segment Reporting Information [Line Items]
TOTAL ASSETS	5,528	6,800	24,756
Corporate Segment [Member]
Segment Reporting Information [Line Items]
TOTAL ASSETS	$ 1,166	$ 4,528	$ 52,989
Medical Technology Segment [Member]
Segment Reporting Information [Line Items]
TOTAL ASSETS

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income tax rate reconciliation:
Tax benefit at U.S. statutory rate	$ 337,000	$ 370,000
Amortization of discount on convertible notes payable	(136,000)	(160,000)
Valuation allowance	$ (201,000)	$ (210,000)
Income tax expense

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Jan. 20, 2016	Jun. 06, 2015	May. 29, 2015	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Subsequent Event [Line Items]
Conversion of convertible notes to common stock				$ 199,959	$ 369,322	$ 401,582	$ 446,109
Conversion of convertible notes and interest into common stock, shares				27,841,559		113,585
Convertible Promissory Note Dated April 1, 2014 [Member]
Subsequent Event [Line Items]
Conversion of convertible notes to common stock						$ 158,260
Conversion of convertible notes and interest into common stock, shares						52,754
Convertible Promissory Note Dated June 30, 2013 [Member]
Subsequent Event [Line Items]
Conversion of convertible notes to common stock						$ 4,954
Conversion of convertible notes and interest into common stock, shares						1,239
Convertible Promissory Note Dated September 30, 2013 [Member]
Subsequent Event [Line Items]
Conversion of convertible notes to common stock						$ 238,368
Conversion of convertible notes and interest into common stock, shares						59,592
Subsequent Event [Member]
Subsequent Event [Line Items]
Reincorporation, date			May 29, 2015
Reincorporation, state			Nevada
Subsequent Event [Member] | 10% Convertible Note Payable Due June 30, 2016 [Member]
Subsequent Event [Line Items]
Conversion of convertible notes to common stock	$ 2,388
Conversion of convertible notes and interest into common stock, shares	119,418
Subsequent Event [Member] | Convertible Promissory Note Dated June 30, 2014 [Member]
Subsequent Event [Line Items]
Date		Jun. 6, 2015
Debt instrument, face amount		$ 62,980
Conversion of convertible notes to common stock		$ 13,600
Conversion of convertible notes and interest into common stock, shares		680,000
Subsequent Event [Member] | Convertible Promissory Note Dated December 31, 2014 [Member]
Subsequent Event [Line Items]
Date		Jun. 1, 2015
Debt instrument, face amount		$ 125,059
Conversion of convertible notes to common stock		$ 130,267
Conversion of convertible notes and interest into common stock, shares		6,513,344